Euroscreen commented today on their recent, joint Nature publication with Novartis revealing the discovery of a novel therapeutic target for the treatment of immune disorders. A recent issue of Nature, described the identification of 7α-25-dihydroxycholesterol (7α,25-OHC) as the natural ligand for the EBI2 G-protein coupled receptor (‘GPCR’), also known as GPR183.